SEARCH:   Advanced

Blood, 1 September 2006, Vol. 108, No. 5, pp. 1451-1460. Prepublished online as a Blood First Edition Paper on April 25, 2006; DOI 10.1182/blood-2006-02-005017. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2006-02-005017v1 108/5/1451    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Decaudin, D. Articles by Rouic, L. L.-L. Search for Related Content PubMed PubMed Citation Articles by Decaudin, D. Articles by Rouic, L. L.-L. Related Collections Neoplasia Review Articles Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  REVIEW ARTICLES Ocular adnexal lymphoma: a review of clinicopathologic features and treatment options Didier Decaudin, Patricia de Cremoux, Anne Vincent-Salomon, Remi Dendale, and Livia Lumbroso-Le Rouic From the Department of Clinical Hematology/Unité mixte de recherché (UMR) 144, Centre National de la Recherche Scientifique (CNRS), Institut Curie; the Department of Tumor Biology, Institut Curie; the Department of Radiation Oncology, Institut Curie; and the Department of Ophthalmology, Institut Curie, Paris, France. The recent literature shows that interest in ocular adnexal lymphomas and their biologic and clinical characteristics—along with their possible association with Chlamydia psittaci infection and therapeutic management with rituximab or anti-Chlamydia psittaci antibiotic therapy—is considerable. These new data have modified the previously reported features of this disease and have made an updated review of the literature necessary. The aims of this review are to present the current knowledge on the biology of these lymphomas, their clinical features and prognostic factors, and the panel of all available treatment options. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: B. Esmaeli, P. McLaughlin, B. Pro, F. Samaniego, I. Gayed, F. Hagemeister, J. Romaguera, F. Cabanillas, S. S. Neelapu, R. Banay, et al. Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma Ann. Onc., April 1, 2009; 20(4): 709 - 714. [Abstract] [Full Text] [PDF] L. D. Sjo, S. Heegaard, J. U. Prause, B. L. Petersen, S. Pedersen, and E. Ralfkiaer Extranodal Marginal Zone Lymphoma in the Ocular Region: Clinical, Immunophenotypical, and Cytogenetical Characteristics Invest. Ophthalmol. Vis. Sci., February 1, 2009; 50(2): 516 - 522. [Abstract] [Full Text] [PDF] O. Maksimovic, W. A. Bethge, J. P. Pintoffl, M. Vogel, C. D. Claussen, R. Bares, and M. Horger Marginal Zone B-Cell Non-Hodgkin's Lymphoma of Mucosa-Associated Lymphoid Tissue Type: Imaging Findings Am. J. Roentgenol., September 1, 2008; 191(3): 921 - 930. [Abstract] [Full Text] [PDF] R Sahli, D Canioni, J Couturier, G Soler, C Mathiot, O Galatoire, L L.-L. Rouic, M Puttermann, O Hermine, P Validire, et al. Bilateral MALT-type ocular adnexal lymphoma with marginal zone lymphoma leukaemic cells and ophthalmological diffuse large B cell lymphoma Br J Ophthalmol, April 1, 2008; 92(4): 579 - 580. [Full Text] [PDF] E.-K. Song, S.-Y. Kim, T. M. Kim, K.-W. Lee, T. Yun, I.-I. Na, H. Shin, S. H. Lee, D. W. Kim, S. I. Khwarg, et al. Efficacy of chemotherapy as a first-line treatment in ocular adnexal extranodal marginal zone B-cell lymphoma Ann. Onc., February 1, 2008; 19(2): 242 - 246. [Abstract] [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020